Ananda Amarasinghe
Overview
Explore the profile of Ananda Amarasinghe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mekonnen D, Bauri M, Pogo M, Shang M, Bettels D, Kabir S, et al.
Western Pac Surveill Response J
. 2024 Jan;
14(4):1-6.
PMID: 38230256
Objective: Routine immunization coverage in Papua New Guinea has decreased in the past 5 years. This persistently low routine immunization coverage has resulted in low population immunity and frequent outbreaks...
2.
Cho H, Amarasinghe A, Takashima Y
Western Pac Surveill Response J
. 2023 Jul;
14(2):1-6.
PMID: 37492237
Problem: Novel vaccines were developed in an unprecedentedly short time in response to the global coronavirus disease (COVID-19) pandemic, which triggered concerns about the safety profiles of the new vaccines....
3.
Amarasinghe A, Cho H, Katalbas E, Takashima Y
Western Pac Surveill Response J
. 2023 Jul;
14(2):1-11.
PMID: 37492235
The speed at which new vaccines against coronavirus disease (COVID-19) were developed and rolled out as part of the global response to the pandemic was unprecedented. This report summarizes COVID-19...
4.
Abou-Nader A, Heffelfinger J, Amarasinghe A, Nelson E
PLOS Glob Public Health
. 2023 Mar;
2(8):e0000801.
PMID: 36962480
This study explored the demand and interest among countries in the World Health Organization Western Pacific Region (WPR) to establish and participate in a regional vaccine pooled procurement mechanism. National...
5.
Gold M, Amarasinghe A, Greenhawt M, Kelso J, Kochhar S, Thong B, et al.
Vaccine
. 2022 Nov;
41(15):2605-2614.
PMID: 36435707
The Brighton Collaboration (BC) has formulated a number of case definitions which have primarily been applied to adverse events of special interest in the context of vaccine safety surveillance. This...
6.
Gidudu J, Shaum A, Habersaat K, Wilhelm E, Woodring J, Mast E, et al.
Vaccine
. 2019 Jul;
38(49):7728-7740.
PMID: 31337590
The success of immunization programs in lowering the incidence of vaccine preventable diseases (VPDs) has led to increased public attention on potential health risks associated with vaccines. As a result,...
7.
Amarasinghe A, Davison L, Diorditsa S
Vaccine
. 2018 Jul;
36(32 Pt B):4958-4962.
PMID: 30037486
Financial sustainability of national immunization programmes (NIPs) in the Western Pacific is a growing concern. In the face of decreasing donor support for public immunization programmes, the role of private...
8.
Uehara A, Tissera H, Bodinayake C, Amarasinghe A, Nagahawatte A, Tillekeratne L, et al.
Am J Trop Med Hyg
. 2017 Jul;
97(1):130-136.
PMID: 28719296
The four serotypes of dengue virus (DENV-1, -2, -3, and -4) have had a rapidly expanding geographic range and are now endemic in over 100 tropical and subtropical countries. Sri...
9.
Tissera H, Weeraman J, Amarasinghe A, Wijewickrama A, Palihawadana P, Fernando L
WHO South East Asia J Public Health
. 2017 Jun;
3(1):5-7.
PMID: 28607248
No abstract available.
10.
Jayasekara H, De Silva A, Amarasinghe A
WHO South East Asia J Public Health
. 2017 Jun;
5(2):149-154.
PMID: 28607243
Background: Immunization is regarded as the single most cost-effective way to prevent vaccine-preventable diseases. With the rising cost of the National Immunization Programme (NIP) in Sri Lanka, immunization costing studies...